332 related articles for article (PubMed ID: 34037408)
41. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
[TBL] [Abstract][Full Text] [Related]
42. EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2023 Apr; 55(2):498-505. PubMed ID: 36228655
[TBL] [Abstract][Full Text] [Related]
43. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
44. Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui C; Qu V; Wang JY; von Eyben R; Chang YC; Chiang PL; Liang CH; Lu JT; Li G; Hayden-Gephart M; Wakelee H; Neal J; Ramchandran K; Das M; Nagpal S; Soltys S; Myall N; Pollom E
J Neurooncol; 2022 Oct; 160(1):233-240. PubMed ID: 36227422
[TBL] [Abstract][Full Text] [Related]
45. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
[TBL] [Abstract][Full Text] [Related]
46. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia.
Sutandyo N; Suratman E
Acta Med Indones; 2018 Oct; 50(4):291-298. PubMed ID: 30630993
[TBL] [Abstract][Full Text] [Related]
47. Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test.
Qu BL; Cai BN; Yu W; Liu F; Huang YR; Ju ZJ; Wang XS; Ou GM; Feng LC
Neoplasma; 2016; 63(1):158-62. PubMed ID: 26639246
[TBL] [Abstract][Full Text] [Related]
48. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
[TBL] [Abstract][Full Text] [Related]
49. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?
Shi AA; Digumarthy SR; Temel JS; Halpern EF; Kuester LB; Aquino SL
J Thorac Oncol; 2006 Mar; 1(3):205-10. PubMed ID: 17409858
[TBL] [Abstract][Full Text] [Related]
50. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
51. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
52. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.
Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J
Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450
[TBL] [Abstract][Full Text] [Related]
53. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
[TBL] [Abstract][Full Text] [Related]
54. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
Eichler AF; Kahle KT; Wang DL; Joshi VA; Willers H; Engelman JA; Lynch TJ; Sequist LV
Neuro Oncol; 2010 Nov; 12(11):1193-9. PubMed ID: 20627894
[TBL] [Abstract][Full Text] [Related]
55. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
56. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
57. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
58. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Shi Y; Au JS; Thongprasert S; Srinivasan S; Tsai CM; Khoa MT; Heeroma K; Itoh Y; Cornelio G; Yang PC
J Thorac Oncol; 2014 Feb; 9(2):154-62. PubMed ID: 24419411
[TBL] [Abstract][Full Text] [Related]
59. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
[TBL] [Abstract][Full Text] [Related]
60. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.
Dawood S; Lei X; Litton JK; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Oct; 118(19):4652-9. PubMed ID: 22359359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
